Thanks, Acclivity. I was unimpressed by the Sharp appointment - couldn't see what special US expertise or contacts he would bring, and only another director to receive fees - unless one of the others intends to resign .
As to sales - very unlikely to be a significant increase in the quarter just finishing. I am always looking for problems; one possible one might be that the sales for the quarter will be underwhelming , and the costs higher, and disappointed holders might sell .
All the best, Mirri
Ann: ImpediMed Achieves Critical Mass in First Key Target State, page-15
Add IPD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $119.3M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6000 | 6.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.1¢ | 121721 | 2 |
View Market Depth
| Last trade - 10.04am 04/10/2024 (20 minute delay) ? |
| IPD (ASX) Chart |
Day chart unavailable